The Regeneron Prescribed drugs firm brand is seen on a constructing on the firm’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Image taken September 17, 2020. REUTERS/Brendan McDermid
Oct 11 (Reuters) – The European Union’s medicine regulator mentioned it was evaluating a advertising and marketing authorisation for an antibody cocktail developed by Roche (ROG.S) and Regeneron (REGN.O) for the remedy and prevention of COVID-19 in individuals above the age of 12.
The European Medicines Company mentioned on Monday it’s going to assess the dangers and advantages of the drug, known as Ronapreve, and that it may concern an opinion inside two months. The company has already began a rolling overview of the remedy.
Reporting by Yadarisa Shabong in Bengaluru
Our Requirements: The Thomson Reuters Trust Principles.
0 Comments